Breaking News: Intercept’s FDA Advisory Committee Meeting for Obeticholic Acid Yields Promising Results in Treating Pre-Cirrhotic Fibrosis Due to NASH
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH Yesterday, the FDA Advisory Committee met to discuss the benefits and risks of using OCA 25 mg as a treatment for NASH patients with stage 2 or 3 fibrosis. The outcome of the meeting was…